Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum

Neuroscience Letters

Volumn 59, Issue 3, 1985, Pages 259-264

  Ricaurte, G A ^a,c   Langston, J W ^b,c   DeLanney, L E ^c   Irwin, I ^c   Brooks, J D ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); dopamine; mouse; neostriatum; neurotoxicity; Parkinson's disease; substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMFEBUTAMONE; AMFONELIC ACID; ATROPINE; BENZATROPINE MESILATE; DOPAMINE; MAZINDOL; NEUROTOXIN; TRIHEXYPHENIDYL;

ANIMAL CELL; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DRUG EFFICACY; DRUG INTERACTION; DRUG RECEPTOR BINDING; MOUSE; NONHUMAN; PARKINSON DISEASE; PHARMACOKINETICS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 84886642215     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(85)90141-7     Document Type: Article

References (24)

1. A primate model of Parkinson's disease: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
2. Selective neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in subhuman primates and man: a new animal model of Parkinson's disease
3. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
4. Neurochemical and histochemical characterization of neurotoxic effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse
5. Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse
6. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
7. + in the substantia nigra: a key to neurotoxicity?
8. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP
9. MPTP and Parkinson's disease
10. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
11. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey
12. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra
13. The importance of the ‘4–5’ double bond for neurotoxicity in primates of the pyridine derivative MPTP
14. Pargyline prevents MPTP-induced parkinsonism in primates
15. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
16. Simultaneous multiple electrode liquid chromatograph-electrochemical assay for catecholamines, indoleamines, and metabolites in brain tissue
17. Fluoxetine increases long-lasting neostriatal dopamine depletion after d-methamphetamine and d-amphetamine
18. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase A and B and suicide inactivation of the enzymes by MPTP
19. Dopamine depletion in rat brain by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
20. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain and heart